Hi Gaboy, unfortunately biotech requires patience. This strategy is truly brilliant, because we are not retraining the thinking of doctors. They are comfortable with the PSA test. This new recaf test using this synthetic peptide only boosts results of the PSA. It's like taking an engine and adding a turbo supercharger. Same engine, more efficient. It will be widely accepted. It is a no brainer for doctors, patients, and certainly insurance companies, therefore, it should be a no brainer for investors.